{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:11:59Z","timestamp":1789506719799,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006041","name":"Innovate UK","doi-asserted-by":"publisher","award":["97163"],"award-info":[{"award-number":["97163"]}],"id":[{"id":"10.13039\/501100006041","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.vaccine.2026.128927","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T21:14:34Z","timestamp":1783718074000},"page":"128927","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Protective titre of the WHO international standard for anti-chikungunya virus antibodies in a mouse model"],"prefix":"10.1016","volume":"88","author":[{"given":"Stuart D.","family":"Dowall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Findlay-Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria A.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Yara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Easterbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Salguero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Ruedas-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Crossley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Kempster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Almond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.vaccine.2026.128927_bb0005","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41579-025-01177-8","article-title":"Chikungunya virus and other emerging arthritogenic alphaviruses","volume":"23","author":"de Souza","year":"2025","journal-title":"Nat. Rev. Microbiol."},{"issue":"4","key":"10.1016\/j.vaccine.2026.128927_bb0010","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ejim.2012.01.009","article-title":"Chikungunya fever","volume":"23","author":"Kucharz","year":"2012","journal-title":"Eur J Intern Med"},{"issue":"26","key":"10.1016\/j.vaccine.2026.128927_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.126483","article-title":"Chikungunya vaccine development, challenges, and pathway toward public health impact","volume":"42","author":"Maure","year":"2024","journal-title":"Vaccine"},{"issue":"13","key":"10.1016\/j.vaccine.2026.128927_bb0020","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.1128\/JVI.01603-09","article-title":"Genome-scale phylogenetic analyses of chikungunya virus reveal independent emergences of recent epidemics and various evolutionary rates","volume":"84","author":"Volk","year":"2010","journal-title":"J. Virol."},{"issue":"12","key":"10.1016\/j.vaccine.2026.128927_bb0025","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1995-7645(14)60164-4","article-title":"Chikungunya virus, epidemiology, clinics and phylogenesis: a review","volume":"7","author":"Lo Presti","year":"2014","journal-title":"Asian Pac J Trop Med"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128927_bb0030","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S1473-3099(23)00810-1","article-title":"Chikungunya seroprevalence, force of infection, and prevalence of chronic disability after infection in endemic and epidemic settings: a systematic review, meta-analysis, and modelling study","volume":"24","author":"Kang","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.vaccine.2026.128927_bb0035","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.coviro.2016.09.014","article-title":"Chikungunya: an unexpected emergence in Europe","volume":"21","author":"Amraoui","year":"2016","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.vaccine.2026.128927_bb0040","article-title":"Chikungunya virus: from genetic adaptation to pandemic risk and prevention","volume":"12","author":"Shandhi","year":"2025","journal-title":"Ther Adv Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128927_bb0045","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/epirev\/mxz012","article-title":"CEPI: driving Progress toward epidemic preparedness and response","volume":"41","author":"Gouglas","year":"2019","journal-title":"Epidemiol. Rev."},{"key":"10.1016\/j.vaccine.2026.128927_bb0050","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.antiviral.2018.09.009","article-title":"The WHO R&D blueprint: 2018 review of emerging infectious diseases requiring urgent research and development efforts","volume":"159","author":"Mehand","year":"2018","journal-title":"Antivir. Res."},{"issue":"43","key":"10.1016\/j.vaccine.2026.128927_bb0055","doi-asserted-by":"crossref","first-page":"6241","DOI":"10.1016\/j.vaccine.2019.09.009","article-title":"UK vaccines network: mapping priority pathogens of epidemic potential and vaccine pipeline developments","volume":"37","author":"Noad","year":"2019","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128927_bb0060","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taaf118","article-title":"Chikungunya vaccination for travellers: practical guidance for clinical decision-making","volume":"32","author":"Hills","year":"2025","journal-title":"J Travel Med"},{"issue":"32","key":"10.1016\/j.vaccine.2026.128927_bb0065","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2025.30.32.2500543","article-title":"Surveillance for adverse events following use of live attenuated chikungunya vaccine, United States, 2024, and the associated public health response in 2024 and 2025","volume":"30","author":"Hills","year":"2025","journal-title":"Euro Surveill"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128927_bb0070","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1473-3099(25)00552-3","article-title":"More data needed on the FDA's decision to suspend Ixchiq","volume":"25","author":"The Lancet Infectious, D","year":"2025","journal-title":"Lancet Infect. Dis."},{"issue":"44","key":"10.1016\/j.vaccine.2026.128927_bb0075","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2025.30.44.2500792","article-title":"Post-authorisation experience and reported adverse events following use of a virus-like particle chikungunya vaccine, United States and Germany, up to august 2025","volume":"30","author":"Simone","year":"2025","journal-title":"Euro Surveill"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128927_bb0080","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.bsheal.2025.10.001","article-title":"Chikungunya virus: current situation and future challenges","volume":"7","author":"Zhao","year":"2025","journal-title":"Biosaf Health"},{"key":"10.1016\/j.vaccine.2026.128927_bb0085","series-title":"WHO\/BS\/2022\/2434: Collaborative study to evaluate a candidate World Health Organization international standard for antibodies to chikungunya virus","author":"Baylis","year":"2022"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128927_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/v16101534","article-title":"Comparison of chikungunya virus-induced disease progression and pathogenesis in type-I interferon receptor-deficient mice (A129) and two wild-type (129Sv\/Ev and C57BL\/6) mouse strains","volume":"16","author":"Graham","year":"2024","journal-title":"Viruses"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128927_bb0095","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jcv.2007.05.008","article-title":"Molecular diagnosis and analysis of chikungunya virus","volume":"39","author":"Edwards","year":"2007","journal-title":"J. Clin. Virol."},{"issue":"2","key":"10.1016\/j.vaccine.2026.128927_bb0100","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.vaccine.2019.10.009","article-title":"Towards quantification of protective antibody responses by passive transfer of the 1st WHO international standard for Ebola virus antibody in a guinea pig model","volume":"38","author":"Dowall","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128927_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2024.199409","article-title":"Convalescent human plasma candidate reference materials protect against Crimean-Congo haemorrhagic fever virus (CCHFV) challenge in an A129 mouse model","volume":"346","author":"Kempster","year":"2024","journal-title":"Virus Res."},{"issue":"2","key":"10.1016\/j.vaccine.2026.128927_bb0110","doi-asserted-by":"crossref","first-page":"527","DOI":"10.20506\/rst.17.2.1118","article-title":"International standards for test methods and reference sera for diagnostic tests for antibody detection","volume":"17","author":"Wright","year":"1998","journal-title":"Rev. Sci. Tech."},{"issue":"9","key":"10.1016\/j.vaccine.2026.128927_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(24)00097-1","article-title":"Harmonising the measurement of neutralising antibodies against chikungunya virus: a path forward for licensing of new vaccines?","volume":"5","author":"Baylis","year":"2024","journal-title":"Lancet Microbe"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128927_bb0120","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taae123","article-title":"From bench to clinic: the development of VLA1553\/IXCHIQ, a live-attenuated chikungunya vaccine","volume":"31","author":"Chen","year":"2024","journal-title":"J Travel Med"},{"issue":"14","key":"10.1016\/j.vaccine.2026.128927_bb0125","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.160173","article-title":"Effectiveness of CHIKV vaccine VLA1553 demonstrated by passive transfer of human sera","volume":"7","author":"Roques","year":"2022","journal-title":"JCI Insight"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128927_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003764","article-title":"High rate of subclinical chikungunya virus infection and association of neutralizing antibody with protection in a prospective cohort in the Philippines","volume":"9","author":"Yoon","year":"2015","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.vaccine.2026.128927_bb0135","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ijid.2020.03.073","article-title":"Pre-existing chikungunya virus neutralizing antibodies correlate with risk of symptomatic infection and subclinical seroconversion in a Philippine cohort","volume":"95","author":"Yoon","year":"2020","journal-title":"Int. J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.vaccine.2026.128927_bb0140","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41541-025-01360-1","article-title":"Passive transfer of human sera from chikungunya virus virus-like particle vaccine (Vimkunya) recipients fully protects non-human primates from viremia","volume":"11","author":"Morello","year":"2026","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2026.128927_bb0145","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.591885","article-title":"Adenoviral-vectored Mayaro and chikungunya virus vaccine candidates afford partial cross-protection from lethal challenge in A129 mouse model","volume":"11","author":"Campos","year":"2020","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.vaccine.2026.128927_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens8040231","article-title":"A single and un-Adjuvanted dose of a chimpanzee adenovirus-vectored vaccine against chikungunya virus fully protects mice from lethal disease","volume":"8","author":"Campos","year":"2019","journal-title":"Pathogens"},{"issue":"27","key":"10.1016\/j.vaccine.2026.128927_bb0155","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1016\/j.vaccine.2018.05.095","article-title":"A recombinant virus vaccine that protects against both chikungunya and Zika virus infections","volume":"36","author":"Chattopadhyay","year":"2018","journal-title":"Vaccine"},{"issue":"33","key":"10.1016\/j.vaccine.2026.128927_bb0160","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1016\/j.vaccine.2013.05.059","article-title":"Deciphering the protective role of adaptive immunity to CHIKV\/IRES a novel candidate vaccine against chikungunya in the A129 mouse model","volume":"31","author":"Chu","year":"2013","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128927_bb0165","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02449-17","article-title":"Chikungunya virus strains show lineage-specific variations in virulence and cross-protective ability in murine and nonhuman primate models","volume":"9","author":"Langsjoen","year":"2018","journal-title":"mBio"},{"issue":"16","key":"10.1016\/j.vaccine.2026.128927_bb0170","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1016\/j.vaccine.2011.01.076","article-title":"Probing the attenuation and protective efficacy of a candidate chikungunya virus vaccine in mice with compromised interferon (IFN) signaling","volume":"29","author":"Partidos","year":"2011","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128927_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002970","article-title":"A novel MVA vectored chikungunya virus vaccine elicits protective immunity in mice","volume":"8","author":"Weger-Lucarelli","year":"2014","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"Suppl. 5","key":"10.1016\/j.vaccine.2026.128927_bb0180","doi-asserted-by":"crossref","first-page":"S482","DOI":"10.1093\/infdis\/jiw284","article-title":"Animal models of chikungunya virus infection and disease","volume":"214","author":"Haese","year":"2016","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.vaccine.2026.128927_bb0185","doi-asserted-by":"crossref","DOI":"10.3390\/v17010062","article-title":"Chikungunya: from hypothesis to evidence of increased severe disease and fatalities","volume":"17","author":"Brito","year":"2025","journal-title":"Viruses"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2600736X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2600736X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:45:23Z","timestamp":1789505123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2600736X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":37,"alternative-id":["S0264410X2600736X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128927","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protective titre of the WHO international standard for anti-chikungunya virus antibodies in a mouse model","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128927","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128927"}}